Saturday, September 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 4, 2026

A Look At Perimeter Solutions (PRM) Valuation After UBS Upgrade To Buy

View original at finance.yahoo.com
A Look At Perimeter Solutions (PRM) Valuation After UBS Upgrade To Buy Never miss an important update on your stock portfolio and cut through the noise…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The estimated fair P/S ratio is 4.4x based on SWS models if expectations cool

    60% confidence

  • Analysts see more than 25% upside to their price targets for Perimeter Solutions

    60% confidence

  • Perimeter Solutions rating upgraded from Neutral to Buy with a higher price target

    60% confidence

  • Current P/S of 5.9x suggests Perimeter Solutions is overvalued

    60% confidence

  • Perimeter Solutions revenue is forecast to grow at 12.9% per year compared with 10.4% for the US market

    60% confidence

  • Perimeter Solutions at $25.59 trades at a 50.3% discount to an estimated future cash flow value of $51.45 based on DCF model

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com
A Look At Perimeter Solutions (PRM) Valuation After UBS Upgrade To Buy — Source | Via News | Via News